The Tel Aviv-based firm develops powder-based Intranasal specialised therapies.
Israeli firm Nasus Pharma (NYSE: NSRX), which develops powder-based Intranasal specialised therapies, has introduced the completion of its IPO, elevating $10 million at an organization valuation of $75 million, after cash. Laidlaw & Firm (UK) Ltd. and Craft Capital Administration LLC are appearing as joint book-runners for the providing.
This has been a uncommon pharmaceutical flotation in latest months, after the sector has seen share costs persistently fall since 2021. There have additionally been few IPOs of Israeli firms in recent times.
Nasus was based in 2019 by VP growth Dr. Dalia Megiddo and chairman Udi Gilboa, who’ve beforehand held flotations for Alcobra and Bioblast. Dan Teleman is CEO of Nasus. In accordance with the prospectus, Nasus solely has two workers.
NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free different to Epinephrine auto-injectors for sufferers with anaphylaxis. Intranasal administration is most fitted for these conditions wherein speedy drug supply is required and provides needle free, straightforward to make use of options. Nasus proprietary powder-based intranasal (“PBI”) expertise is designed for speedy and dependable drug supply, leveraging the nasal cavity’s wealthy vascular community for fast absorption. The PBI formulation makes use of uniform spherical powder particles for broad dispersion and doubtlessly sooner, increased absorption in comparison with liquid-based nasal merchandise.
Printed by Globes, Israel enterprise information – en.globes.co.il – on August 13, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
